News

James J. Hsieh, MD,&nbsp;discusses differential overall survival (OS) results of the RECORD-3 study based on 3 distinct mRCC molecular subgroups, classified by patients who harbored <em>BAP1</em> and/or <em>PBRM1</em> mutations.

Novel immunotherapy agents continue to move through the pipeline in the treatment landscape of bladder cancer, and they show no signs of slowing down.

The addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to the MEK inhibitor cobimetinib (Cotellic) and the BRAF inhibitor vemurafenib (Zelboraf) induced a high response rate for patients with <em>BRAF</em>-mutant unresectable melanoma.

The FDA has expanded the approval for bevacizumab (Avastin) in ovarian cancer to include patients with platinum-sensitive recurrent disease as part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to Genentech, which developed the drug.

Regorafenib (Stivarga) demonstrates the first survival benefit in second-line setting for patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib, according to results of the phase III RESORCE trial published in <em>The Lancet</em>.

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. Mark Stein, MD, says that they can even serve as clinical endpoints in trials.

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended.

While mouse models have historically been helpful in the research of immunotherapies, genetic testing and clinical models may play a role in the near future.&nbsp;These pre-clinical models have been criticized for some of their limitations, but Marcus Bosenberg, MD, PhD, confirms their current relevance and clinical applicability.<br /> &nbsp;

Michael Morse, MD, discusses treatment considerations and options for 2 cases of patients with colorectal cancer

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.

Jeffery S. Weber, MD, PhD, discusses treatment considerations and options for 3 cases of patients with metastatic melanoma.

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.

Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma.

Findings of a new study revealed that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care (SOC) for the disease.

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

Clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD.

The American Society of Hematology (ASH) has announced that it will honor the late David Grimwade, PhD, with the 2016 Exemplary Service Award.

Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.

According to updated study findings, pembrolizumab (Keytruda) reduced the size of tumors in patients with a subtype of soft tissue sarcoma.

Daratumumab (Darzalex)&nbsp;has received FDA approval in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Based on encouraging efficacy signals and safety data from separate trials exploring the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor durvalumab (MEDI4736), there is a role for checkpoint inhibitors in the treatment of glioblastoma multiforme (GBM).

The antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma (GBM).

Findings from a recent phase II study&nbsp;showed the PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-na&iuml;ve patients with recurrent glioblastoma multiforme (GBM).

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields device.

The FDA has issued a complete response letter to&nbsp;Spectrum Pharmaceuticals for apaziquone (EOquin; Qapzola) in bladder cancer.&nbsp;<br /> &nbsp;